Short Interest in Enfusion, Inc. (NYSE:ENFN) Declines By 19.6%

Enfusion, Inc. (NYSE:ENFN) saw a significant decline in short interest in November. As of November 30th, there was short interest totalling 820,400 shares, a decline of 19.6% from the November 15th total of 1,020,000 shares. Approximately 1.7% of the company’s stock are sold short. Based on an average trading volume of 404,000 shares, the short-interest ratio is currently 2.0 days.

Insider Buying and Selling

In related news, COO Neal Pawar sold 21,801 shares of Enfusion stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.03, for a total transaction of $218,664.03. Following the transaction, the chief operating officer now owns 1,143,544 shares of the company’s stock, valued at $11,469,746.32. The trade was a 1.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 36.44% of the stock is currently owned by company insiders.

Institutional Trading of Enfusion

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its position in shares of Enfusion by 7.3% during the third quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock valued at $9,770,000 after acquiring an additional 70,367 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Enfusion by 6.7% during the 3rd quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock valued at $9,265,000 after purchasing an additional 61,032 shares during the last quarter. State Street Corp raised its stake in shares of Enfusion by 2.3% during the 3rd quarter. State Street Corp now owns 952,895 shares of the company’s stock worth $9,043,000 after purchasing an additional 21,729 shares during the period. Impax Asset Management Group plc boosted its holdings in shares of Enfusion by 25.4% in the 3rd quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock worth $6,424,000 after buying an additional 136,948 shares during the last quarter. Finally, Scalar Gauge Management LLC grew its position in Enfusion by 21.8% during the second quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock valued at $5,227,000 after buying an additional 110,000 shares during the period. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Enfusion Stock Down 0.4 %

NYSE:ENFN traded down $0.04 during trading hours on Monday, hitting $10.61. 567,420 shares of the company traded hands, compared to its average volume of 383,757. The company has a market cap of $1.36 billion, a PE ratio of 266.25, a PEG ratio of 3.98 and a beta of 0.97. The firm’s 50-day simple moving average is $9.53 and its 200-day simple moving average is $8.95. Enfusion has a one year low of $7.52 and a one year high of $10.74.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.